Market Overview

UPDATE: Morgan Stanley Upgrades Align Technology to Equal-Weight on Trends, Limited Competition

Related ALGN
Medical Device Co. Align Technology Has Clear Upside, Says Leerink
Trial Date Set For Traders Accused Of $100 Million Hacking Scheme

Morgan Stanley raised its rating on Align Technology (NASDAQ: ALGN) from Underweight to Equal-weight and suspended its previous $25 price target.

Morgan Stanley said, "Our Underweight thesis anticipated pressure from consumer spending and competition. Consumer pressure has emerged and pressured growth and valuation, but FDA barriers continue to restrain potential competitors while buying time for Align to expand its low end product line and reduce price to limit potential discounts from new entrants. Our base case forecast for ~8-10% organic growth in 2013 (1% < consensus) reflects (i) stable 10% new customer adds per year; (ii) price decline moderation to -3%; and (iii) utilization growth, particularly in the orthodontist channel. We assume US discretionary spend recovers, competitors are slow to capture share if approved, and Align wins in litigation vs. ClearCorrect; visibility on each is limited."

Align Technology closed at $28.40 on Wednesday.

Latest Ratings for ALGN

Jul 2015Stifel NicolausMaintainsBuy
Apr 2015Morgan StanleyUpgradesEqual-weightOverweight
Jan 2015JMP SecuritiesDowngradesMarket OutperformMarket Perform

View More Analyst Ratings for ALGN
View the Latest Analyst Ratings

Posted-In: Morgan StanleyAnalyst Color Upgrades Intraday Update Analyst Ratings


Related Articles (ALGN)

View Comments and Join the Discussion!

Get Benzinga's Newsletters